ANGELICOLA, STEFANIA
 Distribuzione geografica
Continente #
EU - Europa 330
AS - Asia 264
NA - Nord America 135
AF - Africa 19
SA - Sud America 1
Totale 749
Nazione #
CN - Cina 208
IT - Italia 198
US - Stati Uniti d'America 134
NL - Olanda 46
SG - Singapore 37
DE - Germania 22
CI - Costa d'Avorio 14
FI - Finlandia 13
IE - Irlanda 10
AT - Austria 9
CH - Svizzera 9
HK - Hong Kong 9
SE - Svezia 7
RU - Federazione Russa 5
GB - Regno Unito 4
DK - Danimarca 2
FR - Francia 2
ID - Indonesia 2
JO - Giordania 2
PK - Pakistan 2
TG - Togo 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BR - Brasile 1
EE - Estonia 1
EG - Egitto 1
HR - Croazia 1
IN - India 1
JP - Giappone 1
KG - Kirghizistan 1
MA - Marocco 1
MX - Messico 1
ZA - Sudafrica 1
Totale 749
Città #
Shanghai 165
Bologna 67
Singapore 30
Milan 20
Casalecchio di Reno 16
Abidjan 14
Houston 13
Ashburn 11
Dublin 10
Santa Clara 10
Bern 9
Hong Kong 9
Boardman 7
Chandler 7
Helsinki 7
Kerpen 7
Vicenza 7
Vienna 7
Lappeenranta 6
New York 6
Bo 5
Cimitile 5
Amsterdam 4
Cambridge 4
Council Bluffs 4
Fairfield 4
Los Angeles 4
Beijing 3
Boydton 3
Castenaso 3
Falkenstein 3
Parma 3
Porto Recanati 3
Rimini 3
Southend 3
Turin 3
Wilmington 3
Woodbridge 3
Amman 2
Bremen 2
Cento 2
Chieti 2
Guangzhou 2
Jakarta 2
Lomé 2
Modena 2
Princeton 2
San Benedetto del Tronto 2
Seattle 2
Alfortville 1
Ann Arbor 1
Berlin 1
Bishkek 1
Cavenago Di Brianza 1
Changsha 1
Changyuan 1
Cologno Monzese 1
Correggio 1
Costa Volpino 1
Dalian 1
Florence 1
Frankfurt am Main 1
Guaíra 1
Harbin 1
Hounslow 1
Islamabad 1
Jiangmen 1
Kagoya 1
Langfang 1
Lauterbourg 1
Manassas 1
Medford 1
Mexico City 1
Montescudo 1
Monza 1
Muizenberg 1
Mülheim 1
Newark 1
Orzinuovi 1
Peshawar 1
Portici 1
Qingdao 1
Rabat 1
Redmond 1
Reggio Emilia 1
San Diego 1
Shenzhen 1
Sofia 1
Suzhou 1
Tallinn 1
Toenisvorst 1
Vanløse 1
Wuhan 1
Zhengzhou 1
Totale 558
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 334
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 102
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 81
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 78
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 39
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 38
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 37
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 34
Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis 31
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 22
Totale 796
Categoria #
all - tutte 2.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.269


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202138 0 0 0 0 0 0 9 18 6 1 2 2
2021/202227 3 3 1 2 5 3 1 0 3 1 3 2
2022/2023108 2 2 2 11 13 13 12 5 16 3 13 16
2023/2024270 5 2 21 17 16 13 7 175 2 6 2 4
2024/2025353 10 33 18 15 52 27 76 40 6 76 0 0
Totale 796